← Back to home

Inflammation Drug Fails to Cut Heart Risk in Kidney Patients

Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources

Brief

Ziltivekimab, a Novo Nordisk antibody that blocks the inflammatory protein interleukin-6, failed to reduce heart attacks, strokes, or deaths from heart disease among adults who…

Keep reading with NewsPlain Premium

Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.

2 sources behind this story.

About this story

We haven’t published a correction to this story.

How NewsPlain works
← Back to home